Patents Represented by Attorney Lester E. Johnson
-
Patent number: 5028430Abstract: An implantable polymeric delivery system for the controlled and continuous administration of an LHRH agonist which comprises a silicone elastomer matrix in which is dispersed about 30 to about 42 weight percent of water-soluble particulate phase containing an LHRH analog or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 8, 1987Date of Patent: July 2, 1991Assignee: Syntex (U.S.A.) Inc.Inventors: Lynda M. Sanders, Ramon A. Burns, Jr.
-
Patent number: 4970297Abstract: This invention is directed to compounds of the formula: ##STR1## or an optical isomer thereof, or a pharmaceutically acceptable salt thereof, wherein:n is 0, 1 or 2;p and q are independently 0, 1 or 2 and the sum of (p+q) is less than or equal to 3;X is selected from the group consisting of: halo; --OR.sup.2, --SR.sup.2, --S(O)R.sup.2, --S(O).sub.2 R.sup.2, and --S(O).sub.2 NHR.sup.2, wherein R.sup.2 is lower alkyl, mono-, di- or tri-fluoro alkyl of 2 or 3 carbon atoms, optionally substituted aryl;R is H or an N-protecting group;R.sup.1 is alkylthio, arylthio, amino, alkylamino, optionally substituted arylamino, or optionally substituted aralkylamino; and when the sum of n+p+q is greater than or equal to one, R.sup.1 is also hydroxy, alkoxy, or aralkoxy; andeach (aa) is independently an .alpha.-amino acid residue with an optionally protected amino acid side chain.Type: GrantFiled: March 13, 1987Date of Patent: November 13, 1990Assignee: Syntex (U.S.A.) Inc.Inventors: Arlindo L. Castelhano, Diana H. Pliura, Michael C. Venuti
-
Patent number: 4962091Abstract: An active agent delivery system for the controlled administration of macromolecular polypeptides which comprises a micro-suspension of water-soluble components in a polylactide matrix.Type: GrantFiled: May 23, 1986Date of Patent: October 9, 1990Assignee: Syntex (U.S.A.) Inc.Inventors: Deborah A. Eppstein, Brian B. Schryver
-
Patent number: 4940556Abstract: A long acting sustained release pharmaceutical composition for dihydropyridine calcium channel blockers wherein the calcium channel blocker and a pH-dependent binde are intimately admixed in essentially spherically shaped non-rugose particles of up to 1.2 mm in diameter.Type: GrantFiled: July 26, 1987Date of Patent: July 10, 1990Assignee: Syntex (U.S.A.) Inc.Inventors: Calum B. MacFarlane, Alastair B. Selkirk, Michael J. Dey
-
Patent number: 4929630Abstract: The present invention is directed to certain 3,5 substituted, 4,5-dihydroisoxazoles, and methods for their use. These compounds are transglutaminase inhibitors, and are particularly effective in the inhibition of epidermal transglutaminase and the treatment of acne.Type: GrantFiled: September 8, 1989Date of Patent: May 29, 1990Assignee: Syntex (U.S.A.) Inc.Inventors: Arlindo L. Castelhano, Lawrence M. DeYoung, Alexander Krantz, Diana H. Pliura, Michael C. Venuti
-
Patent number: 4912120Abstract: The present invention is directed to certain 3,5 substituted, 4,5-dihydroisoxazoles, and methods for their use. These compounds are transgulatminase inhibitors, and are particularly effective in the inhibition of epidermal transglutaminase and the treatment of acne.Type: GrantFiled: March 13, 1987Date of Patent: March 27, 1990Assignee: Syntex (U.S.A.) Inc.Inventors: Arlindo L. Castelhano, Lawrence M. DeYoung, Alexander Krantz, Diana H. Pliura, Michael C. Venuti
-
Patent number: 4873232Abstract: Novel alkoxycarbonylamino benzoates and related copounds (carbamoyl benzoates) are disclosed for treatment of auto-immune disease states, such as arthritis.Type: GrantFiled: October 29, 1986Date of Patent: October 10, 1989Assignee: SyntexInventors: Alexander Krantz, John M. Young
-
Patent number: 4720385Abstract: Compositions containing therapeutically or immunologically active proteins are rendered substantially free from infectious agents such as viable viruses and bacteria without substantial loss of therapeutic or immunologic activity by mixing the protein composition with a complex formed from transition metal ions, such as copper ions, and an angularly-fused, polynuclear heterocyclic arene having two nitrogen atoms in a "cis-ortho" relationship, such as phenanthroline, and a reducing agent such as a thiol or ascorbic acid or ascorbate salt or mixtures of ascorbic acid or ascorbate with a thiol in amounts and at a temperature and for a time sufficient to inactivate substantially all of the viruses and bacteria contained therein. Compositions containing therapeutically active proteins substantially free from viral and bacterial infectivity, which have heretofore been unattainable, can be prepared by the method of the invention.Type: GrantFiled: May 20, 1985Date of Patent: January 19, 1988Assignee: Miles Laboratories, Inc.Inventor: Kenneth J. Lembach
-
Patent number: 4713246Abstract: A liquid dosage form suitable for oral administration of etoposide which is sufficiently concentrated to be administered in capsule form and which provides improved absorption of the drug relative to prior oral formulations.Type: GrantFiled: April 2, 1986Date of Patent: December 15, 1987Assignee: Bristol-Myers CompanyInventors: Selima Begum, Ismat Ullah, Bernard C. Nunning
-
Patent number: 4697003Abstract: There is disclosed a method for separating alpha-1-proteinase inhibitor (also known as alpha-1 antitrypsin) from an aqueous solution of plasma proteins, especially from Cohn Effluent II & III and Cohn Effluent I. The method includes the steps of first treating the aqueous solution to lower the concentration of salts therein and, optionally, its alcohol content, contacting the resulting solution with an anion exchange resin having selective affinity for alpha-1-proteinase inhibitor to selectively bind the alpha-1-proteinase inhibitor and allow unwanted plasma proteins to elute through the resin, displacing the alpha-1-proteinase inhibitor from the resin and recovering the same.Type: GrantFiled: November 1, 1985Date of Patent: September 29, 1987Assignee: Miles Laboratories, Inc.Inventor: Michael H. Coan
-
Patent number: 4684723Abstract: There is disclosed an improved method for separating and recovering proteins, particularly therapeutically active proteins, from an aqueous system also containing a component having the ability to create two liquid phases by use of salt partitioning technology. By the addition of water soluble inorganic salts to an aqueous system containing one or more therapeutically active proteins or nucleic acids, especially an aqueous system obtained from fractionation of a blood plasma fraction or from a tissue culture fluid resulting from a biotechnology production operation such as recombinant DNA and monoclonal antibody technologies, the aqueous system may be separated into two or more liquid phases. Such separated phases may be selectively enriched in components of the original aqueous system having differing solubility in the so-separated liquid phases.Type: GrantFiled: September 11, 1985Date of Patent: August 4, 1987Assignee: Miles Laboratories, Inc.Inventors: George B. Dove, Gautam Mitra
-
Patent number: 4663160Abstract: An immunizing composition is disclosed and comprises a detoxified polysaccharide from a gram-negative bacterium covalently coupled to a detoxified protein from said gram-negative bacterium by means of a 4-12 carbon moiety. To prepare the above immunizing agent, the lipid A portion of lipopolysaccharide from a gram-negative bacterium is separated to give a detoxified polysaccharide. Reactive aldehyde groups are generated on the detoxified polysaccharide by selective oxidation. The detoxified polysaccharide is then covalently coupled to a detoxified protein from said gram-negative bacterium by means of a 4-12 carbon moiety having functionalities reactive to the aldehyde groups on the detoxified polysaccharide and to the carboxylic groups on the detoxified protein.Type: GrantFiled: March 14, 1983Date of Patent: May 5, 1987Assignee: Miles Laboratories, Inc.Inventors: Grace C. Tsay, Michael S. Collins
-
Patent number: 4656254Abstract: There is disclosed an improved method for separating one of alpha-1-proteinase inhibitor (also known as alpha-1 antitrypsin) and antithrombin-III from an aqueous solution of plasma proteins containing the same, such as from Cohn Fraction IV-1, Cohn Fraction IV, reworks of Cohn Fraction IV and IV-1, Cohn Effluent II & III and Cohn Effluent I. The method includes the steps of first holding an aqueous solution of plasma proteins containing one of alpha-1-proteinase inhibitor and antithrombin-III in a relatively large volume of buffer solution as solvent and at a pH adjusted to be relatively basic when compared to conditions heretofore known, and at a temperature in the range of from 2.degree.-50.degree. C. for a period of about 0.2-24 hours. Following the above treatment, alpha-1-proteinase inhibitor and antithrombin-III are obtained by applying conventional techniques to the resulting solution. Accordingly, the solution is then mixed with a polyalkylene glycol, e.g.Type: GrantFiled: December 2, 1985Date of Patent: April 7, 1987Assignee: Miles Laboratories, Inc.Inventors: Michael A. Shearer, Pamela K. Sasagawa, Ronald H. Hein
-
Patent number: 4649048Abstract: Particular quaternized vinylimidazole-ethylene glycol dimethacrylate copolymers are useful to sequester non-absorbed bile acids in the intestinal tract to form a complex which is excreted in the feces.Type: GrantFiled: December 23, 1985Date of Patent: March 10, 1987Assignee: Bristol-Myers CompanyInventor: Porter C. Johnson
-
Patent number: 4617379Abstract: Normal plasma from donors who have not been vaccinated with a cytomegalovirus vaccine can be screened for higher than normal titers of naturally occurring antibody to cytomegalovirus. Those plasmas with high titers of such antibody can be pooled and fractionated to give hyperimmune serum globulin. The product may be treated to render it suitable for intravenous injection. Patients with cytomegalovirus infection or at risk to such infection, may receive the present product to raise serum titers of cytomegalovirus antibody.Type: GrantFiled: June 14, 1983Date of Patent: October 14, 1986Assignee: Miles Laboratories, Inc.Inventors: Milton B. Dobkin, Robert E. Louie
-
Patent number: 4604430Abstract: Particular quaternized vinylimidazole-ethylene glycol dimethacrylate copolymers are useful to sequester non-absorbed bile acids in the intestinal tract to form a complex which is excreted in the feces.Type: GrantFiled: May 11, 1984Date of Patent: August 5, 1986Assignee: Bristol-Myers CompanyInventor: Porter C. Johnson
-
Patent number: 4600578Abstract: Oral administration of particular quaternized vinylimidazole-ethylene glycol dimethacrylate copolymers inhibits diarrhea.Type: GrantFiled: May 11, 1984Date of Patent: July 15, 1986Assignee: Bristol-Myers CompanyInventors: Anthony W. Pircio, Joseph P. Buyniski, William T. Comer
-
Patent number: 4587121Abstract: Normal plasma from donors who have not been vaccinated with a Pseudomonas vaccine or had a Pseudomonas infection can be screened for higher than normal titers of naturally occurring antibody to four of seven Fisher Immunotypes for Pseudomonas. Those plasmas with higher titers of such antibody can be pooled and fractionated to give hyperimmune serum globulin having high titers of antibody against all seven Fisher Immunotypes. The product may be treated to render it intravenously injectable and the so-prepared material is effective in treating patients with Pseudomonas infection.Type: GrantFiled: June 17, 1983Date of Patent: May 6, 1986Assignee: Miles Laboratories, Inc.Inventors: Michael S. Collins, Robert E. Roby
-
Patent number: 4543210Abstract: There is disclosed an improved process for producing high purity antihemophilic factor concentrate from an antihemophilic factor-containing dispersion or solution isolated from blood plasma or a blood plasma fraction, wherein the improvement is in carrying-out two consecutive precipitations using a combination of precipitants in each precipitation, first a combination of 1-4% by weight, based on weight of solution, of polyethylene glycol and 0.1-0.2 ml of 1-3%, based on weight of suspension, aluminum hydroxide suspension per gram of protein in the starting dispersion or solution, followed by a combination of added polyethylene glycol to provide a final concentration of 9-13% by weight, based on weight of the resulting solution, and 10-20% by weight of glycine, based on weight of the polyethylene glycol solution, and 10-20% by weight, based on weight of the polyethylene glycol solution, of sodium chloride.Type: GrantFiled: October 4, 1984Date of Patent: September 24, 1985Assignee: Miles Laboratories, Inc.Inventors: Gautam Mitra, Paul K. Ng
-
Patent number: 4534972Abstract: Compositions containing therapeutically or immunologically active proteins are rendered substantially free from infectious agents such as viable viruses and bacteria without substantial loss of therapeutic or immunologic activity by mixing the protein composition with a complex formed from source of transition metal ions, such as copper ions, and an angularly-fused, polynuclear heterocyclic arene having two nitrogen atoms in a "cis-ortho" relationship, such as phenanthroline, and a reducing agent such as a thiol in amounts and at a temperature and for a time sufficient to inactivate substantially all of the viruses and bacteria contained therein. Compositions containing therapeutically active proteins substantially free from viral and bacterial infectivity, which have heretofore been unattainable, can be prepared by the method of the invention.Type: GrantFiled: March 29, 1983Date of Patent: August 13, 1985Assignee: Miles Laboratories, Inc.Inventor: Kenneth J. Lembach